Home » AGEB Journal » Issues » Volume 86" » Fasc.3 - Clinical images » Article details

An unusual cause of portal hypertension

Journal Volume 86 - 2023
Issue Fasc.3 - Clinical images
Author(s) K. Ferdinande 1, T. Lamiroy 1, A. Hoorens 2, X. Verhelst 1, H. Degroote 1, S. Raevens 1, H. Van Vlierberghe 1, A. Geerts 1
Full article
Full Article
PAGES 509-510
(1) Department of Gastroenterology and Hepatology, Ghent University Hospital, Belgium
(2) Department of Pathology, Ghent University Hospital, Belgium

A 66-year-old male with a medical history of coronary artery disease presented with nonspecific symptoms of anorexia, lethargy and an increase in abdominal girth. He was diagnosed 3 months ago with chronic liver disease of undetermined aetiology. He did not smoke and was a social drinker till 4 months ago. He was taking tests showed progressive cholestatic liver enzymes (total bilirubin 1,09 mg/dL, AST 130 U/L, ALT 129 U/L, GGT 517 U/L and ALP 641 U/L) and a severe hypoalbuminemia. Laboratory workup made a metabolic, autoimmune, and viral aetiology of the suspected cirrhosis less probable. Urinalysis showed a rapidly progressive proteinuria in the nephrotic range accompanied by the presence of serum spike of monoclonal lambda light Furosemide, Aldactone, Pantoprazole, Acetylcysteine and Atorvastatin. He had no personal or familial history of liver diseases. Physical examination revealed a tender but distended abdomen and large ascites was present. The laboratory chain protein on electrophoresis with immunofixation. Doppler echocardiography revealed a hypertrophic cardiomyopathy based on diffuse left and right ventricular hypertrophy with relative apical sparing. A diagnostic paracentesis was undertaken and the results were consistent with portal hypertension (SAAG 1,6 g/ dL). Considering the concomitant presence of hypertrophic cardiomyopathy, nephrotic syndrome and a presentation of portal hypertension of undetermined aetiology in presence of a monoclonal IgG lambda light chain spike, a transjugular liver biopsy (figure 1 and 2) was performed with HVPG measurement consistent with significant portal hypertension (15 mmHg).

Keywords: hepatic amyloidosis, portal hypertension’, infiltrative liver diseases.

The authors declare that they have no conflict of interest.
© Acta Gastro-Enterologica Belgica.
PMID 37814574